Here’s What Wall Street Thinks Of Chimerix After The Crash

Chimerix Inc CMRX 3.58% shares were crushed on Monday, as the stock fell more than 80 percent following news that its brincidofovir SUPPRESS study fell short of endpoint expectations in the prevention of cytomegalovirus (CMV) infection.

After the big fall, is it time to stick a fork in Chimerix, or has the panic selloff created a value opportunity? Here’s what three top Wall Street firms have to say about Chimerix now.

Barclays

Analyst Geoff Meacham believes it’s “premature to write off brincidofovir just yet,” but the firm reduced its price target from $65 to $12 following the news.

Meacham will be looking for data on the adenovirus (AdV) approvability based on the AdVise study outcome and resumption of the solid organ transplant studies (SOT) within the next six months. The firm maintains an Outperform rating on the stock.

FBR & Co

Analyst Ed White pointed…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common SenseI don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!